Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Total Current Liabilities
All obligations due within one year.
Medifast, Inc.NYSE: MED
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 30.4% from a year ago
Total current liabilities stood at $42.18M at the end of Q1 FY2026, down 30.4% from a year earlier and down 1.8% from the prior quarter. Over 3 fiscal years it compounded at -32.7% a year.
Context
- Total current liabilities amounted to 16.7% of total assets at the end of Q1 FY2026, down 4.9 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -30.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 42.96M USD
- Year-over-year change
- -33.0%
- 4-year CAGR
- -29.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.96M | -33.0% |
| FY2024 | 2024-12-31 | 64.16M | -30.5% |
| FY2023 | 2023-12-31 | 92.3M | -34.5% |
| FY2022 | 2022-12-31 | 140.89M | -17.0% |
| FY2021 | 2021-12-31 | 169.83M | — |
Total Current Liabilities vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -30.4% is the 9th highest of 10, against a peer median of -2.6%.
- Total current liabilities amounts to 16.7% of total assets for MED, versus a peer median of 27.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $541.44M USD | +18.6% | +14.1% | 54.1% | |
| May 2026 | $260.37M USD | +12.2% | -2.3% | 64.7% | |
| Dec 2025 | HK$135.46M HKD | -36.3% | -23.7% | 44.6% | |
| Mar 2026 | $105.51M USD | +7.7% | +5.9% | 26.5% | |
AIIORobo.ai Inc. | Jun 2025 | $102.86M USD | -0.9% | +25.4% | 294.4% |
| Feb 2026 | $71.82M USD | -2.6% | -8.6% | 22.7% | |
| Jan 2026 | $48.79M USD | -2.8% | +8.3% | 27.7% | |
| Mar 2026 | $42.18M USD | -30.4% | -32.7% | 16.7% | |
| Mar 2026 | $37.98M USD | -5.1% | -14.4% | 15.6% | |
| Mar 2026 | $24.9M USD | -15.2% | -2.2% | 20.4% | |
| Peer median (excluding MED) | — | -2.6% | -2.2% | 27.7% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 104.18M | 87.69M | 94.44M | 90.93M | 89.3M |
| Short-term Investments | 5.36M | 0 | 55.6M | 71.42M | 77.97M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 180.04M | 118.86M | 54.59M | 42.42M | 20.23M |
| Other Current Assets | 16.33M | 1 | 0 | 0 | 9.07M |
| Total Current Assets | 306.87M | 222.78M | 224.03M | 214.4M | 201.68M |
| Property, Plant & Equipment (Net) | 80.59M | 75.65M | 67.11M | 48.68M | 38.46M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 4.4M | 5.33M | 4.12M | 11.46M | 9.04M |
| Other Non-current Assets | 6.47M | 12.46M | 14.65M | 9.67M | 7.83M |
| Total Non-current Assets | 91.46M | 93.43M | 85.88M | 69.81M | 55.33M |
| Total Assets | 398.33M | 316.21M | 309.91M | 284.21M | 257.01M |
| Account Payables | 70.89M | 53.12M | 39.19M | 23.05M | 15.07M |
| Short-term Debt | 0 | 0 | 0 | 0 | 4.6M |
| Tax Payables | 2.57M | 7.55M | 9.86M | 1.49M | 5.12M |
| Deferred Revenue | 8.05M | 7.36M | 574K | 316K | 384K |
| Other Current Liabilities | 0 | 0 | 0 | 32.77M | 13.63M |
| Total Current Liabilities | 169.83M | 140.89M | 92.3M | 64.16M | 42.96M |
| Long-term Debt | 0 | 0 | 0 | 0 | 6.09M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 9.04M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (6.09M) |
| Total Non-current Liabilities | 26.02M | 20.28M | 16.13M | 9.94M | 15.13M |
| Total Liabilities | 195.85M | 161.17M | 108.43M | 74.1M | 58.09M |
| Common Stock | 12K | 11K | 11K | 11K | 11K |
| Retained Earnings | 190.33M | 139.85M | 174.65M | 176.78M | 158.27M |
| Accumulated OCI | 111K | 24K | 248K | 180K | 234K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 202.47M | 155.04M | 201.48M | 210.11M | 198.92M |
| Total Debt | 32.54M | 26.05M | 22.01M | 16.13M | 16.79M |
| Net Debt | (71.64M) | (61.64M) | (72.43M) | (74.8M) | (72.52M) |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.